A Minipress antilipidaemiás hatásáról.

Translated title of the contribution: The anti-lipidemic effect of Minipress

G. Pados, J. Iványi, I. Földes, M. Dudás, C. Farsang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with "familial dyslipidemic hypertension". When choosing an antihypertensive drug metabolic side effects should be taken into consideration.

Translated title of the contributionThe anti-lipidemic effect of Minipress
Original languageHungarian
Pages (from-to)1139-1141
Number of pages3
JournalOrvosi hetilap
Volume131
Issue number21
Publication statusPublished - May 27 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The anti-lipidemic effect of Minipress'. Together they form a unique fingerprint.

  • Cite this

    Pados, G., Iványi, J., Földes, I., Dudás, M., & Farsang, C. (1990). A Minipress antilipidaemiás hatásáról. Orvosi hetilap, 131(21), 1139-1141.